Spondyloarthritis & psoriatic arthritis
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea
Authors' conclusion
EAIRs of TB and IBD with use of IL-17is in patients with AS were within anticipated low range. IL-17is had numerically lower incidence of TB, and numerically higher incidence of IBD compared with TNFis.
Study context
- Population
- Korean patients with AS receiving biologics
- Exposure
- bDMARD exposures vs bDMARD non-exposure
- Outcome
- Incidence rates of TB and IBD
Methodological detailsclaims database, Korea, 2010–2021, Crude incidence rates calculated from number of events and total patient-years (PYs)
- Claims database
- Korea, 2010–2021
- Crude incidence rates calculated from number of events and total PYs
Main finding
As reported in the abstract
| Group | Value | Inflammatory bowel disease (IBD) EAIR per 100 PYs |
|---|---|---|
| Non-exposure | 0.14 per 100 PYs (tuberculosis (TB)) | 0.18 |
| TNF inhibitors (TNFis) | 0.25 per 100 PYs (TB) | 0.19 |
| IL-17is | 0.12 per 100 PYs (TB) | 0.44 |
Value
Non-exposure0.14 per 100 PYs (TB)
TNF inhibitors (TNFis)0.25 per 100 PYs (TB)
IL-17is0.12 per 100 PYs (TB)
Inflammatory bowel disease (IBD) EAIR per 100 PYs
Non-exposure0.18
TNF inhibitors (TNFis)0.19
IL-17is0.44
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| TB incidence rate by agent, per 10 000 PYs | Non-exposure 13.96 per 10 000 PYs · Adalimumab 27.79 per 10 000 PYs · Etanercept 14.28 per 10 000 PYs · Golimumab 21.19 per 10 000 PYs · Infliximab 33.62 per 10 000 PYs · Secukinumab 12.74 per 10 000 PYs · Ixekizumab 0.00 per 10 000 PYs |
| IBD incidence rate by agent, per 10 000 PYs | Non-exposure 18.29 per 10 000 PYs · Adalimumab 19.98 per 10 000 PYs · Etanercept 22.41 per 10 000 PYs · Golimumab 18.85 per 10 000 PYs · Infliximab 15.73 per 10 000 PYs · Secukinumab 44.99 per 10 000 PYs · Ixekizumab 0.00 per 10 000 PYs |
TB incidence rate by agent, per 10 000 PYs
- Adalimumab, golimumab and infliximab vs bDMARD non-exposure: significantly higher risk of TB
- Etanercept and secukinumab: no significant increase in risk of TB
IBD incidence rate by agent, per 10 000 PYs
- Biologics vs bDMARD non-exposure: no significant difference in risk of IBD
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea. Rheumatology (Oxford). Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →